In this talk, we will discuss the following topics:
Johnson and Johnson's vaccine is different from others because it is a single-shot vaccine.
Phase III trial interim results of the J&J vaccines showing
a) 100% protection from COVID related deaths
b) 85% protection from the severe COVID disease
c) 66% overall efficacy
Countries in which the vaccine trial is conducted
The reason for lesser efficacy in South Africa
Side effects are similar to a placebo that is not too bad
Mobeen Syed is the CEO of DrBeen Corp, a modern online medical education marketplace. Mobeen is a medical doctor and a software engineer. He graduated from the prestigious King Edward Medical University Lahore. He has been teaching medicine since 1994. Mobeen is also a software engineer and engineering leader. In this role, Mobeen has run teams consisting of hundreds of engineers and millions of dollars of budgets. Mobeen loves music, teaching, and doing business. He lives in Cupertino CA.